Average cost of multi drug-resistant tuberculosis treatment in Russian Federation
Russian Federation: Average cost of multi drug-resistant tuberculosis treatment was 2,751 constant 2022 US$ in 2024. ▬ Flat
Latest (2024)
2,751 constant 2022 US$
Change on year
down 4.4%
World rank
18th
of 92 countries
All-time high
3,107 constant 2022 US$
in 2017
All-time low
2,327 constant 2022 US$
in 2019
Years of data
7
2017–2024
Average cost of multi drug-resistant tuberculosis treatment in Russian Federation, 2017–2024
Source: WHO (2025) – with minor processing by Our World in Data. Measured in constant 2022 US$.
Analysis
Russian Federation recorded 2,751 constant 2022 US$ for average cost of multi drug-resistant tuberculosis treatment in 2024.
Compared with earlier readings it is down 4.4% on the previous year and down 11.5% over ten years.
That places Russian Federation 18th out of 92 countries with data for 2024, putting it in the top quarter.
Average cost of multi drug-resistant tuberculosis treatment in Russian Federation, year by year
| Year | constant 2022 US$ | Change |
|---|---|---|
| 2017 | 3,107 constant 2022 US$ | — |
| 2018 | 2,507 constant 2022 US$ | -19.3% |
| 2019 | 2,327 constant 2022 US$ | -7.2% |
| 2020 | 2,683 constant 2022 US$ | +15.3% |
| 2022 | 2,964 constant 2022 US$ | +10.5% |
| 2023 | 2,877 constant 2022 US$ | -2.9% |
| 2024 | 2,751 constant 2022 US$ | -4.4% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 2,647 constant 2022 US$ | 2,327 constant 2022 US$ | 3,107 constant 2022 US$ | 3 |
| 2020s | 2,819 constant 2022 US$ | 2,683 constant 2022 US$ | 2,964 constant 2022 US$ | 4 |
Countries ranked near Russian Federation
More health data for Russian Federation
- Un projection of annual infant deaths, annual growth rate -0.7261 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.5159 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,176 deaths per 1,000 people (2090)
- Number of infants who die before age 1 957 deaths (2100)
- Population ages 50-54, male, annual growth rate 1.15 % change on previous year (2025)
- Population ages 50-54, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 50-54, male, per capita 0.031 units per person (2025)
- Population ages 55-59, female, annual growth rate -1.28 % change on previous year (2025)
- Population ages 55-59, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 55-59, female, per capita 0.0315 units per person (2025)
Frequently asked questions
- What is average cost of multi drug-resistant tuberculosis treatment in Russian Federation?
- Average cost of multi drug-resistant tuberculosis treatment in Russian Federation was 2,751 constant 2022 US$ in 2024, according to WHO (2025) – with minor processing by Our World in Data.
- What is the highest average cost of multi drug-resistant tuberculosis treatment recorded in Russian Federation?
- The highest recorded value was 3,107 constant 2022 US$ in 2017.
- What is the lowest average cost of multi drug-resistant tuberculosis treatment recorded in Russian Federation?
- The lowest recorded value was 2,327 constant 2022 US$ in 2019.
- How does Russian Federation rank for average cost of multi drug-resistant tuberculosis treatment?
- Russian Federation ranks 18th out of 92 countries with data for 2024.
- Is average cost of multi drug-resistant tuberculosis treatment rising or falling in Russian Federation?
- Over the last ten years it is down 11.5%. The long-run trend across the full record is flat.
- Where does this Russian Federation data come from?
- The figures come from WHO (2025) – with minor processing by Our World in Data, published as part of Average cost of multi drug-resistant tuberculosis treatment. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 7 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.